Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation

Florien W Boele^{1

2}, Sé M Frances^{1

3}, Amélie Darlix^{4

5}, Francois Ducray⁶, Stéphanie Cartalat⁷, Estelle Guerdoux^{8

9}, Emeline Tabouret¹⁰, Michael C Burger¹¹, Isabelle Rydén^{12

13}, Annika Malmstrom¹⁴, Elodie Vauleon^{15

16}, Tomas Kazda¹⁷, Mirjam Renovanz¹⁸, Jan-Michael Werner¹⁹, Liam Welsh²⁰, Paul Sanghera²¹, Caroline Dehais²¹, Isacco Desideri^{22

23}, Catherine McBain²⁴, Shaveta Mehta²⁵, Hannah Lord²⁶, Rajesh Jena²⁷, Karen Foweraker²⁸, Keyoumars Ashkan²⁹, Julien Engelhardt³⁰, Veronique Bourg³¹, Ulrich Herrlinger³², Aaron Lawson McLean^{33

34}, Caroline Hertler³⁵, Lene Haldbo-Classen³⁶, Rikke H Dahlrot^{37

38}, Georges Noel³⁹, Xavier Durando⁴⁰, Ioana Hrab⁴¹, Evangelia Razis⁴², Michael Weller⁴³, Aida Muhic⁴⁴, Martin Klein⁴⁵

Affiliations

¹ Leeds Institute of Medical Research at St James's, St James's University Hospital, University of Leeds, Leeds, LS9 7TF, United Kingdom.
² Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, LS2 9JT, United Kingdom.
³ Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, S1 4DA.
⁴ Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier, Montpellier, France.
⁵ Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM, Montpellier, France.
⁶ Hospices Civils de Lyon, Hôpital Neurologique, Neuro-oncology Department; Cancer Research Center of Lyon, Claude Bernard University, Lyon, France.
⁷ Hospices Civils de Lyon, Hôpital Neurologique, Neuro-oncology Department, Lyon, France.
⁸ Department of Palliative and Supportive Care, Montpellier Cancer Institute, Univ Montpellier, Montpellier, France.
⁹ Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.
¹⁰ Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team, APHM, CHU Timone, Service de Neurooncologie, Réseau Préclinique et Translationnel de Recherche en Neuro-oncologie Marseille, France.
¹¹ Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany.
¹² Institute for Neuroscience and Physiology, University of Gothenburg, Sweden.
¹³ Department of Neurology, Sahlgrenska University Hospital, Sweden.
¹⁴ Department of Geriatrics and Palliative Medicine and Division of Cell and Neurobiology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden EV: Centre Eugène Marquis, Medical Oncology, INSERM U1242, University of Rennes, Rennes, France.
¹⁵ Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
¹⁶ Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic.
¹⁷ Tubingen University Hospital, Tubingen, Germany.
¹⁸ Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
¹⁹ The Royal Marsden NHS Foundation Trust, London, UK.
²⁰ Cancer Centre, University Hospitals Birmingham, Edgbaston, Birmingham, B15 2TH, UK.
²¹ Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neuro-oncologie, F-75013, Paris, France.
²² Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
²³ Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
²⁴ Department of Clinical Oncology, The Christie NHS FT, Manchester, UK.
²⁵ The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH634JY, United Kingdom.
²⁶ Tayside NHS Trust, Dundee, UK.
²⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
²⁸ Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK.
²⁹ Department of Neurosurgery, King's College Hospital, London, UK.
³⁰ Department of Neurosurgery, Pellegrin Hospital, Bordeaux University Hospital Center, Bordeaux, France.
³¹ Department of Neurology, Côte d'Azur University, Nice, France.
³² Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.
³³ Department of Neurosurgery, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
³⁴ Comprehensive Cancer Center Central Germany, Jena Campus, Jena, Germany.
³⁵ Competence Center Palliative Care, Dept. of Radiation Oncology, University Hospital and University of Zurich, Zurich, Switzerland.
³⁶ The Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital, Denmark.
³⁷ Department of Oncology, Odense University Hospital, Odense, Denmark.
³⁸ Dept. of Clinical Research, University of Southern Denmark, Odense, Denmark.
³⁹ radiotherapy department, Institut de Cancérologie de Strasbourg-Europe (ICANS), 17, rue Albert Calmette, F-67200 Strasbourg, France.
⁴⁰ INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand F- 63000, France ; 2 Centre d'Investigation Clinique UMR501, Clermont-Ferrand F-63000, France ; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand F-63000, France ; Service d'oncologie médicale, Centre Jean PERRIN, Clermont-Ferrand F-63000, France.
⁴¹ Centre Francois Baclesse, Caen, France.
⁴² 3rd Oncology Department, Hygeia Hospital Athens Greece.
⁴³ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
⁴⁴ Rigshospitalet, Copenhagen, Denmark.
⁴⁵ Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Psychology, Boelelaan 1117, Amsterdam, The Netherlands.

PMID: 40692477
DOI: 10.1093/neuonc/noaf172

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation

Florien W Boele et al. Neuro Oncol. 2025.

. 2025 Jul 19:noaf172.

doi: 10.1093/neuonc/noaf172. Online ahead of print.

Authors

Affiliations

¹ Leeds Institute of Medical Research at St James's, St James's University Hospital, University of Leeds, Leeds, LS9 7TF, United Kingdom.
² Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, LS2 9JT, United Kingdom.
³ Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, S1 4DA.
⁴ Department of Medical Oncology, Montpellier Cancer Institute, University of Montpellier, Montpellier, France.
⁵ Institute of Functional Genomics IGF, University of Montpellier, CNRS, INSERM, Montpellier, France.
⁶ Hospices Civils de Lyon, Hôpital Neurologique, Neuro-oncology Department; Cancer Research Center of Lyon, Claude Bernard University, Lyon, France.
⁷ Hospices Civils de Lyon, Hôpital Neurologique, Neuro-oncology Department, Lyon, France.
⁸ Department of Palliative and Supportive Care, Montpellier Cancer Institute, Univ Montpellier, Montpellier, France.
⁹ Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.
¹⁰ Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team, APHM, CHU Timone, Service de Neurooncologie, Réseau Préclinique et Translationnel de Recherche en Neuro-oncologie Marseille, France.
¹¹ Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany.
¹² Institute for Neuroscience and Physiology, University of Gothenburg, Sweden.
¹³ Department of Neurology, Sahlgrenska University Hospital, Sweden.
¹⁴ Department of Geriatrics and Palliative Medicine and Division of Cell and Neurobiology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden EV: Centre Eugène Marquis, Medical Oncology, INSERM U1242, University of Rennes, Rennes, France.
¹⁵ Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
¹⁶ Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic.
¹⁷ Tubingen University Hospital, Tubingen, Germany.
¹⁸ Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
¹⁹ The Royal Marsden NHS Foundation Trust, London, UK.
²⁰ Cancer Centre, University Hospitals Birmingham, Edgbaston, Birmingham, B15 2TH, UK.
²¹ Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neuro-oncologie, F-75013, Paris, France.
²² Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
²³ Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
²⁴ Department of Clinical Oncology, The Christie NHS FT, Manchester, UK.
²⁵ The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH634JY, United Kingdom.
²⁶ Tayside NHS Trust, Dundee, UK.
²⁷ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
²⁸ Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK.
²⁹ Department of Neurosurgery, King's College Hospital, London, UK.
³⁰ Department of Neurosurgery, Pellegrin Hospital, Bordeaux University Hospital Center, Bordeaux, France.
³¹ Department of Neurology, Côte d'Azur University, Nice, France.
³² Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany.
³³ Department of Neurosurgery, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany.
³⁴ Comprehensive Cancer Center Central Germany, Jena Campus, Jena, Germany.
³⁵ Competence Center Palliative Care, Dept. of Radiation Oncology, University Hospital and University of Zurich, Zurich, Switzerland.
³⁶ The Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital, Denmark.
³⁷ Department of Oncology, Odense University Hospital, Odense, Denmark.
³⁸ Dept. of Clinical Research, University of Southern Denmark, Odense, Denmark.
³⁹ radiotherapy department, Institut de Cancérologie de Strasbourg-Europe (ICANS), 17, rue Albert Calmette, F-67200 Strasbourg, France.
⁴⁰ INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand F- 63000, France ; 2 Centre d'Investigation Clinique UMR501, Clermont-Ferrand F-63000, France ; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand F-63000, France ; Service d'oncologie médicale, Centre Jean PERRIN, Clermont-Ferrand F-63000, France.
⁴¹ Centre Francois Baclesse, Caen, France.
⁴² 3rd Oncology Department, Hygeia Hospital Athens Greece.
⁴³ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
⁴⁴ Rigshospitalet, Copenhagen, Denmark.
⁴⁵ Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Psychology, Boelelaan 1117, Amsterdam, The Netherlands.

PMID: 40692477
DOI: 10.1093/neuonc/noaf172

Abstract

Background: Patients with oligodendroglioma have a relatively favourable prognosis. The long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.

Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumour location; treatments delivered; time since treatment; current medication;) were explored with regression analyses.

Results: In total, 237 patients M=9.9 years post-diagnosis (sd=4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (post-hoc analyses for cumulative radiotherapy dose: not significant).

Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning.

Trial registration: NCT04708548.

Keywords: cognition; health-related quality of life; low-grade glioma; oligodendroglioma; survivorship.

PubMed Disclaimer

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation

Affiliations

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation

Authors

Affiliations

Abstract

Associated data

LinkOut - more resources

Full Text Sources